All articles by  

  1. AstraZeneca reports positive data for Brilinta in stroke patients

    AstraZeneca has reported that the Phase III THALES clinical trial of Brilinta (ticagrelor) has met its primary endpoint in patients…
    Read More…

    27 Jan
  2. Roche’s Tecentriq fails in Phase III urothelial cancer study

    Results from the Phase III IMvigor010 clinical trial have revealed that Roche’s Tecentriq (atezolizumab) did not meet the primary endpoint…
    Read More…

    27 Jan
  3. Ipsen temporarily stops palovarotene dosing in FOP trials

    Ipsen has paused the dosing of patients in Phase II extension and Phase III clinical studies of palovarotene for the…
    Read More…

    27 Jan
  4. BlackThorn begins Phase II dosing of BTRX-140 for depression

    BlackThorn Therapeutics has commenced dosing of BTRX-335140 (BTRX-140) in a proof-of-concept Phase II clinical trial involving patients with major depressive…
    Read More…

    24 Jan
  5. LB Pharmaceuticals starts dosing of schizophrenia drug

    US-based biotechnology company LB Pharmaceuticals has started the dosing of LB-102, a benzamide formulation intended for the treatment of patients…
    Read More…

    23 Jan
  6. Ionis and Akcea announce positive data for hypertriglyceridemia

    Ionis Pharmaceuticals and its affiliate Akcea Therapeutics have reported positive data from the Phase II clinical trial of AKCEA-APOCIII-L conducted…
    Read More…

    23 Jan
  7. Roche says risdiplam met primary endpoint in type 1 SMA patients

    Top-line data from part two of the open-label FIREFISH study has demonstrated that Roche’s risdiplam met the primary endpoint in…
    Read More…

    23 Jan
  8. Rafael Pharmaceuticals studies combination therapy for biliary cancer

    Rafael Pharmaceuticals has partnered with Michigan Medicine to start a Phase Ib/II clinical trial of devimistat (CPI-613) combination for locally…
    Read More…

    22 Jan
  9. Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study

    Aldeyra Therapeutics has enrolled the first patient in a Phase III INVIGORATE clinical trial being conducted to assess reproxalap for…
    Read More…

    22 Jan
  10. BeiGene lung cancer drug tislelizumab meets primary goal in trial

    BeiGene has reported positive data from the Phase III clinical trial of tislelizumab in combination with chemotherapy as a first-line…
    Read More…

    22 Jan
Close
Close
Close

Go Top